AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34932886 — intervention group
Group type: COMPARATOR
Intervention: Control curriculum focused on safety
Number of subjects: 117
Study 32152930 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 32
Study 32152930 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 32
Study 32246792 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting (IG, n=51) for twelve months
Number of subjects: 73
Study 32246792 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting by cycling (IG-C, n=26)
Number of subjects: 73
Study 32246792 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting using public transport and walking (IG-PT, n=25)
Number of subjects: 73
Study 32246792 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=22)
Number of subjects: 73
Study 34390067 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower income categories (annual household incomes of <$50,000)
Number of subjects: 4264
Study 34390067 — intervention group
Group type: EXPERIMENTAL
Intervention: Help-seeking behavior
Number of subjects: 4264
Study 34390067 — intervention group
Group type: EXPERIMENTAL
Intervention: Help received
Number of subjects: 4264
Study 34390067 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and practical concerns
Number of subjects: 4264
Study 33677928 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg, monthly subcutaneous injections)
Number of subjects: 67
Study 33677928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 35460726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vebicorvir (VBR) 300 mg once daily + NrtIs
Number of subjects: 73
Study 35460726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vebicorvir (VBR) + NrtIs
Number of subjects: 73
Study 35460726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + NrtIs
Number of subjects: 73
Study 32638680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy diet with ferric oxide (1%)
Number of subjects: 64
Study 32638680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet with ferric oxide (1%)
Number of subjects: 64
Study 32638680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy diet with Cr2O3 (0.5%)
Number of subjects: 64
Study 32638680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy diet with TiO2 (0.5%)
Number of subjects: 64
Study 32638680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet with Cr2O3 (0.5%)
Number of subjects: 64
Study 32638680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet with TiO2 (0.5%)
Number of subjects: 64
Study 35287509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cows’ milk 20% topical ointment applied once daily for two weeks.
Number of subjects: 99
Study 35287509 — intervention group
Group type: COMPARATOR
Intervention: Novel dressing used for control group, applied once daily for two weeks.
Number of subjects: 99
Study 35287509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cows’ milk 20% topical ointment
Number of subjects: 99
Study 32562763 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic biceps tenodesis (BT)
Number of subjects: 3635
Study 32562763 — intervention group
Group type: COMPARATOR
Intervention: Open biceps tenodesis (BT)
Number of subjects: 3635
Study 32562763 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant subacromial decompression
Number of subjects: 3635
Study 32562763 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant distal clavicle resection
Number of subjects: 3635
Study 32562763 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume surgical facilities
Number of subjects: 3635
Study 35488009 — intervention group
Group type: EXPERIMENTAL
Intervention: TIR intervention group (routine nursing follow‐up and comprehensive nursing intervention based on TIR)
Number of subjects: 140
Study 34188053 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by definitive chemoradiotherapy (CRT)
Number of subjects: 110
Study 34188053 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) alone
Number of subjects: 110
Study 32200585 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Diet (EXD)
Number of subjects: 30
Study 32200585 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (DI)
Number of subjects: 30
Study 32200585 — intervention group
Group type: COMPARATOR
Intervention: Exercise (EX)
Number of subjects: 30
Study 35453054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh placement (experimental group, n = 24)
Number of subjects: 56
Study 35453054 — intervention group
Group type: COMPARATOR
Intervention: Control (no mesh, n = 32)
Number of subjects: 56
Study 33039717 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental external nasal dilator (END)
Number of subjects: 71
Study 35537291 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse blunt extension of the uterine incision during cesarean section
Number of subjects: 0
Study 35537291 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal blunt extension of the uterine incision during cesarean section
Number of subjects: 0
Study 33671166 — intervention group
Group type: EXPERIMENTAL
Intervention: Unripe banana flour (UBF) 21 g/day
Number of subjects: 43
Study 33671166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (waxy corn starch 12 g/day)
Number of subjects: 43
Study 32852460 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 61
Study 32852460 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens (75 mg soy isoflavones, BID)
Number of subjects: 61
Study 32852460 — intervention group
Group type: COMPARATOR
Intervention: Hormone Therapy (0.3 mg conjugated equine oestrogens plus 1.5 mg medroxyprogesterone acetate)
Number of subjects: 61
Study 35182048 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) technique, conducted in six sessions through Sky Room, three times a week
Number of subjects: 126
Study 35182048 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study 32620163 — intervention group
Group type: COMPARATOR
Intervention: Arm A: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle)
Number of subjects: 75
Study 32620163 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: Pegylated liposomal doxorubicin (PLD) + cyclophosphamide + ipilimumab (1 mg intravenously every 6th week) + nivolumab (240 mg intravenously every 2nd week)
Number of subjects: 75
Study 35837209 — intervention group
Group type: EXPERIMENTAL
Intervention: LiSi surface treatment
Number of subjects: 60
Study 35837209 — intervention group
Group type: COMPARATOR
Intervention: Glass-ceramics (Control)
Number of subjects: 60
Study 34924363 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth massage programme
Number of subjects: 479
Study 34924363 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 479
Study 34968876 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a randomized controlled trial of lateral episiotomy or no episiotomy in vacuum extraction
Number of subjects: 384
Study 34968876 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of episiotomy in vacuum extractions
Number of subjects: 384
Study 34968876 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated episiotomies
Number of subjects: 384
Study 34968876 — intervention group
Group type: EXPERIMENTAL
Intervention: Correctly drawn episiotomies
Number of subjects: 384
Study 34968876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranking of episiotomy importance
Number of subjects: 384
Study 32272659 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-sn-1(3)-monoacylglycerol (OM3-MAG) at 2.9 g/day
Number of subjects: 0
Study 32272659 — intervention group
Group type: COMPARATOR
Intervention: OM3-ethyl ester at 3.1 g/day
Number of subjects: 0
Study 32272659 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-free fatty acids (OM3-FFA) at 3.2 g/day
Number of subjects: 0
Study 32272659 — intervention group
Group type: COMPARATOR
Intervention: OM3-triacylglycerols (OM3-TAG) at 1.2 g/day
Number of subjects: 0
Study 32272659 — intervention group
Group type: COMPARATOR
Intervention: OM3 at 1.0 g/day
Number of subjects: 0
Study 35543647 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically informed physical therapy (PIPT)
Number of subjects: 1250
Study 35543647 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1250
Study 33047405 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized 308-nm excimer light
Number of subjects: 36
Study 33047405 — intervention group
Group type: COMPARATOR
Intervention: Targeted 311-nm NB-UVB
Number of subjects: 36
Study 32577026 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 32577026 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study 36192005 — intervention group
Group type: EXPERIMENTAL
Intervention: UV‐modified lamps with UV‐on
Number of subjects: 20
Study 36192005 — intervention group
Group type: COMPARATOR
Intervention: Placebo lamps with UV switched off
Number of subjects: 20
Study 34160125 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office gel with bioactive nanoparticles (n-Bm)
Number of subjects: 66
Study 34160125 — intervention group
Group type: COMPARATOR
Intervention: Control - only in-office gel
Number of subjects: 66
Study 32770859 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily
Number of subjects: 50
Study 32770859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35099991 — intervention group
Group type: EXPERIMENTAL
Intervention: PE diagnostic strategy + usual care
Number of subjects: 0
Study 35099991 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 34314304 — intervention group
Group type: EXPERIMENTAL
Intervention: Food feature posts
Number of subjects: 15
Study 34314304 — intervention group
Group type: EXPERIMENTAL
Intervention: Macronutrient posts
Number of subjects: 15
Study 32093657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 2000 IU/d
Number of subjects: 80
Study 32093657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 37605110 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal machine‐based exercise training programme (twice weekly for 45-60 min over six months)
Number of subjects: 400
Study 37605110 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal machine‐based exercise training programme
Number of subjects: 400
Study 37605110 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 33864337 — intervention group
Group type: EXPERIMENTAL
Intervention: ≤20 W with 20 W laser device (group 1)
Number of subjects: 204
Study 33864337 — intervention group
Group type: EXPERIMENTAL
Intervention: ≤20 W with 30 W laser device (group 2)
Number of subjects: 204
Study 33864337 — intervention group
Group type: EXPERIMENTAL
Intervention: >20 W with 30 W laser device (group 3)
Number of subjects: 204
Study 33864337 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 W laser device (groups 2 and 3)
Number of subjects: 204
Study 33864337 — intervention group
Group type: COMPARATOR
Intervention: 20 W laser device (group 1)
Number of subjects: 204
Study 35714294 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention (7 sessions over 3 weeks)
Number of subjects: 122
Study 35714294 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 122
Study 32575482 — intervention group
Group type: EXPERIMENTAL
Intervention: MyHealthAvatar-Diabetes smartphone app for 8 weeks
Number of subjects: 20
Study 32575482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 35197248 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced online injury prevention programme
Number of subjects: 4050
Study 35197248 — intervention group
Group type: COMPARATOR
Intervention: Regular preparation for the running event (Control)
Number of subjects: 4050
Study 32386747 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 µg GMZ2-CAF01
Number of subjects: 50
Study 32386747 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg GMZ2-CAF01
Number of subjects: 50
Study 32386747 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg GMZ2-alum
Number of subjects: 50
Study 32386747 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (rabies vaccine)
Number of subjects: 50
Study 32386747 — intervention group
Group type: EXPERIMENTAL
Intervention: All GMZ2 vaccinated participants
Number of subjects: 50
Study 32386747 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 50
Study 32386747 — intervention group
Group type: EXPERIMENTAL
Intervention: Treg frequencies on D0 or on D84, and Breg frequency on D84
Number of subjects: 50
Study 34780323 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical fixation (open spinal surgery or minimally invasive stabilisation surgery)
Number of subjects: 12
Study 34780323 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (mobilisation with or without a brace)
Number of subjects: 12
Study 34780323 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment rate
Number of subjects: 12
Study 34780323 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study
Number of subjects: 12
Study 34780323 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon willingness to randomise
Number of subjects: 12
Study 35427495 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month anti-TNF therapy and surgical closure
Number of subjects: 94
Study 35427495 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF therapy for 1 year
Number of subjects: 94
Study 34648734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular long-acting cabotegravir (600 mg) and rilpivirine (900 mg) every 8 weeks
Number of subjects: 1045
Study 34648734 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular long-acting cabotegravir (400 mg) and rilpivirine (600 mg) every 4 weeks
Number of subjects: 1045
Study 34648734 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed virological failure in every 8-week group
Number of subjects: 1045
Study 34648734 — intervention group
Group type: COMPARATOR
Intervention: Confirmed virological failure in every 4-week group
Number of subjects: 1045
Study 34648734 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection site reactions in every 8-week group
Number of subjects: 1045
Study 34648734 — intervention group
Group type: COMPARATOR
Intervention: Injection site reactions in every 4-week group
Number of subjects: 1045
Study 32819728 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intra-articular tranexamic acid (TXA)
Number of subjects: 100
Study 32819728 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g intra-articular tranexamic acid (TXA)
Number of subjects: 100
Study 33638108 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D endovision system
Number of subjects: 139
Study 33638108 — intervention group
Group type: COMPARATOR
Intervention: 4K endovision system
Number of subjects: 139
Study 33952358 — intervention group
Group type: EXPERIMENTAL
Intervention: Models 1-7 (weighted sum scores and unweighted sum score models)
Number of subjects: 1722
Study 33952358 — intervention group
Group type: COMPARATOR
Intervention: Null model (mean post-baseline BDI-II score)
Number of subjects: 1722
Study 35043484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg plus doxazosin 2 mg once daily
Number of subjects: 55
Study 35043484 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 4 mg plus doxazosin 2 mg
Number of subjects: 55
Study 35043484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 34176234 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 40
Study 33661283 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-reflectivity
Number of subjects: 52
Study 33661283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellipsoid zone (EZ)-loss
Number of subjects: 52
Study 33661283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion size for hyper-reflectivity
Number of subjects: 52
Study 33661283 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (BCVA)
Number of subjects: 52
Study 33661283 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading speed
Number of subjects: 52
Study 32035998 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus casei DN114001 combined with two regular yoghurt bacterial strains)
Number of subjects: 1127
Study 32035998 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1127
Study 36408831 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Driving Intervention (OT‐DI)
Number of subjects: 42
Study 36408831 — intervention group
Group type: COMPARATOR
Intervention: Traffic Safety Education (TSE)
Number of subjects: 42
Study 33118677 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobutylamido thiazolyl resorcinol (ITR)
Number of subjects: 24
Study 33118677 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 24
Study 32414676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 451
Study 35346148 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on the Health Belief Model (HBM) with five consecutive weekly sessions
Number of subjects: 112
Study 35346148 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on the Health Belief Model (HBM)
Number of subjects: 112
Study 35346148 — intervention group
Group type: COMPARATOR
Intervention: Routine education delivered by the dental clinic (Control)
Number of subjects: 112
Study 32767288 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (FNB)
Number of subjects: 50
Study 32767288 — intervention group
Group type: COMPARATOR
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 50
Study 33541690 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual teaching aid
Number of subjects: 30
Study 33541690 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study 32544221 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed and suspended elbasvir/grazoprevir
Number of subjects: 11
Study 32544221 — intervention group
Group type: COMPARATOR
Intervention: Whole tablet elbasvir/grazoprevir
Number of subjects: 11
Study 32544221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 11
Study 35933730 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (2, 4, or 6 g)
Number of subjects: 34
Study 35933730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 35933730 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (6 g)
Number of subjects: 34
Study 32945632 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus best supportive care
Number of subjects: 700
Study 32945632 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 700
Study 35555129 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based leg heat therapy (HT), n=15
Number of subjects: 34
Study 35555129 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (CON), n=14
Number of subjects: 34
Study 35610590 — intervention group
Group type: EXPERIMENTAL
Intervention: AVATAR therapy
Number of subjects: 20
Study 33106968 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 300–400 U
Number of subjects: 468
Study 33106968 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 468
Study 36122439 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt Mental Health Care (PMHC)
Number of subjects: 463
Study 36122439 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 463
Study 33504865 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) treatment for SAM
Number of subjects: 364
Study 33504865 — intervention group
Group type: COMPARATOR
Intervention: Outpatient therapeutic care (OTC)
Number of subjects: 364
Study 32087417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 0
Study 32087417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33728436 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin plus nab-paclitaxel
Number of subjects: 166
Study 33728436 — intervention group
Group type: COMPARATOR
Intervention: Daily low-dose carboplatin
Number of subjects: 166
Study 36100893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for recurrence-free survival (RFS)
Number of subjects: 1003
Study 36100893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for overall survival (OS)
Number of subjects: 1003
Study 36100893 — intervention group
Group type: COMPARATOR
Intervention: Nomograms compared to conventional staging systems
Number of subjects: 1003
Study 33843948 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed web-based strengthening exercise and physical activity program supported by automated behavior-change text messages
Number of subjects: 206
Study 33843948 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to a custom-built website with information on OA and exercise
Number of subjects: 206
Study 32116285 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep yogic breathing, listening to religious hymns, listening to flute music
Number of subjects: 400
Study 32116285 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 400
Study 36260986 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite-based intensive lifestyle therapy
Number of subjects: 0
Study 36260986 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34156730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz TNT
Number of subjects: 33
Study 34156730 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz TNT
Number of subjects: 33
Study 34156730 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 Hz TNT
Number of subjects: 33